Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Acro Biomedical (ACBM) Shares Outstanding (Weighted Average) (2016 - 2025)

Acro Biomedical (ACBM) has 8 years of Shares Outstanding (Weighted Average) data on record, last reported at $60.0 million in Q2 2023.

  • For Q2 2023, Shares Outstanding (Weighted Average) changed 0.0% year-over-year to $60.0 million; the TTM value through Jun 2023 reached $60.0 million, changed 0.0%, while the annual FY2020 figure was $47.8 million, 0.0% changed from the prior year.
  • Shares Outstanding (Weighted Average) reached $60.0 million in Q2 2023 per ACBM's latest filing, roughly flat from $60.0 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $60.0 million in Q1 2022 and bottomed at $47.8 million in Q1 2019.
  • Average Shares Outstanding (Weighted Average) over 5 years is $52.3 million, with a median of $47.8 million recorded in 2019.
  • Peak YoY movement for Shares Outstanding (Weighted Average): changed 0.0% in 2019, then increased 25.72% in 2022.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $47.8 million in 2019, then changed by 0.0% to $47.8 million in 2020, then rose by 19.07% to $56.9 million in 2021, then grew by 5.58% to $60.0 million in 2022, then changed by 0.0% to $60.0 million in 2023.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $60.0 million in Q2 2023, $60.0 million in Q1 2023, and $60.0 million in Q3 2022.